Close Menu

CHDI Foundation

Alnylam Pharmaceuticals executives last week disclosed that the company has dropped out of its 50/50 cost- and profit-sharing arrangement with Medtronic for the preclinical RNAi-based Huntington's disease therapy ALN-HTT, opting instead to let its partner incur all expenses assoc

The firm will provide the foundation with structure-based drug discovery services.

Alnylam said that the non-profit CHDI Foundation has agreed to pay up to 50 percent of the costs of advancing a treatment for the disease up through an investigational new drug application filing.

The Galapagos subsidiary will conduct high-content screening and a range of other services for CHDI's Huntington's disease drug development programs.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.